Central
Shimadzu Corporation Expands US Presence with Three New R&D Centers for Pharmaceutical Growth
Shimadzu Corporation, R&D centers, US expansion, pharmaceutical industry, business growth, innovation, technology.
CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements
CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction
Johnson & Johnson Closes Bay Area R&D Facility, Plans New California Innovation Center
Research and Development, Johnson and Johnson, California, Central